Medical treatments at 6 months in hospitalized and ambulatory HFrEF patients in the BRING-UP 3 Heart Failure study - PubMed
2 days ago
- #Heart Failure
- #Medical Registry
- #Guideline-Directed Therapy
- The BRING-UP 3 Heart Failure study aimed to assess the real-world implementation of guideline-directed medical therapy (GDMT) for HFrEF patients.
- This observational, prospective study included 3,201 HFrEF patients from 179 sites, with treatment data available for 2,950 patients at 6 months.
- Mean age of participants was 69±11 years, with 18.0% being female.
- GDMT prescription rates were high at baseline and remained stable over 6 months, with a shift from ACE-I/ARBs to ARNIs and a modest increase in SGLT2i use.
- Quadruple therapy was prescribed in 64.3% of patients at 6 months, with a significant increase in ARNI use (52.9% to 55.9%).
- Dose up-titration of GDMT remained suboptimal, with most agents prescribed at less than 50% of target doses.
- Treatment persistence was excellent, but dose optimization remains a key unmet need in clinical practice.